COMMUNIQUÉS West-GlobeNewswire

Microbix Reports Results for Q4 and Fiscal 2025
18/12/2025
Full-Year Revenues of $18.6 million and Net Loss of $2.2 million MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, [...]
Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
18/12/2025
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ [...]
Enable Injections Announces Regulatory Approval in Saudi Arabia for the EMPAVELI® Injector based on enFuse® Technology
18/12/2025
CINCINNATI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® On-Body Delivery System, today announced that the EMPAVELI ® [...]
Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
18/12/2025
WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan [...]
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
18/12/2025
Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID BriaCell’s Phase 3 clinical [...]
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
18/12/2025
NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's [...]
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
18/12/2025
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term value inflection points, with blinded 6-month interim data [...]
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
18/12/2025
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term value inflection points, with blinded 6-month interim data [...]
Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company
18/12/2025
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) [...]
DXS International plc (AQSE: DXSP): Statement for the 2025 Annual General Meeting
18/12/2025
18 December 2025 DXS INTERNATIONAL PLC (AQSE: DXSP) Statement for the 2025 Annual General Meeting The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and [...]
Confo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric Hypoglycemia
18/12/2025
Candidate selection underscores Confo’s ability to rapidly advance differentiated GPCR-targeting therapeutics and its focus on metabolic and endocrine disorders Ghent, Belgium – December 18, 2025 – Confo Therapeutics , [...]
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
18/12/2025
BioNTech has completed its exchange offer to acquire CureVac Acquisition complements BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing In total, [...]
MUVON Therapeutics Appoints Dr. Christine Günther as Chief Technology Officer
18/12/2025
Zurich, Switzerland, December 18, 2025 – MUVON Therapeutics, a clinical-stage biotechnology company focused on developing a novel platform for the regeneration of skeletal muscle tissue, announces the appointment of [...]
FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor
18/12/2025
Funding to support Phase 1 clinical development of best-in-class PARG inhibitor candidate FORX-428 FORX-428 is potential new treatment option for patients whose cancers are resistant to, or have become resistant to, [...]
EssilorLuxottica and Burberry announce licensing partnership renewal
18/12/2025
EssilorLuxottica and Burberry announce licensing partnership renewal Paris, France and London, United Kingdom (18 December 2025) – EssilorLuxottica and Burberry today announced the renewal of their licensing agreement [...]
EssilorLuxottica et Burberry renouvellent leur accord de licence
18/12/2025
EssilorLuxottica et Burberry renouvellent leur accord de licence Paris, France et Londres, Royaume-Uni (18 décembre 2025) – EssilorLuxottica et Burberry ont annoncé aujourd’hui le renouvellement de leur accord de [...]
DXS International plc (AQSE:DXSP) Notice of Cyber Security Incident
18/12/2025
18 December 2025 DXS INTERNATIONAL PLC (AQSE: DXSP) Notice of Cyber Security Incident The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital [...]
GlucoModicum unveils Sofio™, the world’s first needle-free glucose monitor based on magneto-hydrodynamics (MHD)
18/12/2025
PRESS RELEASE — FOR IMMEDIATE RELEASE GlucoModicum unveils Sofio™, the world’s first needle-free glucose monitor based on magneto-hydrodynamics (MHD) MHD technology draws micro-sample through skin; glucose is measured [...]
Sequana Medical Announces Granting of Key Additional U.S. Patent for DSR
18/12/2025
Ghent, Belgium, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Builds upon existing granted DSR patents in US, Europe, Japan and China Strengthens DSR patent protection based upon extensive clinical and pre-clinical experience Data [...]

Pages